IL-17+ lymphocytes mark low-immunity, EMT-enriched tumors in primary triple-negative breast cancer: investigated in relation to tumor-infiltrating lymphocytes (CD8+, CD4+, FOXP3+) and macrophages (CD163+)
This study reveals that in primary triple-negative breast cancer, IL-17+ lymphocytes define a distinct low-immunity tumor phenotype enriched with epithelial–mesenchymal transition (EMT) features and metabolic reprogramming, contrasting with the favorable prognosis associated with other immune cell infiltrates like CD8+ and CD4+ T cells.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is not a single disease but a collection of different conditions, each behaving in its own way. Among these, triple-negative breast cancer is often the most aggressive. It is called "triple-negative" because the cancer cells lack three specific receptors that doctors usually target with standard hormone therapies or other drugs. Without these targets, treatment relies heavily on chemotherapy, and the outlook can be less favorable than for other types of breast cancer. However, the body's own immune system plays a crucial role in how this disease progresses. Inside the tumor, a complex neighborhood of cells exists, including cancer cells, blood vessels, and various types of immune cells that act as the body's defense force. Some of these immune cells, like certain white blood cells, attack the cancer and help patients survive longer, while others may inadvertently help the cancer grow or hide from the immune system. Understanding exactly which immune cells are present and how they interact is vital for finding better ways to treat this difficult form of cancer.
Researchers in Sweden recently set out to map this immune landscape in a group of 237 patients with early-stage triple-negative breast cancer. They focused on a specific group of immune cells that produce a signaling protein called IL-17. While other immune cells in the tumor are generally known to be helpful, the role of IL-17-producing cells has been unclear. To investigate this, the team examined tissue samples from the patients' tumors. They used a technique that stains specific proteins to count different types of immune cells, including those that attack cancer directly, those that regulate the immune response, and a type of immune cell called a macrophage that lives in the tissue surrounding the tumor. They also analyzed the genetic activity of the tumors to see which biological pathways were turned on or off.
The study revealed a distinct pattern for tumors containing IL-17-producing cells. These tumors were found to be different from those packed with other helpful immune cells. In fact, the presence of IL-17 cells was inversely related to the presence of the beneficial immune cells; when one was high, the others were often low. More importantly, the researchers found that tumors with these IL-17 cells showed signs of a specific biological shift known as the epithelial-mesenchymal transition. This is a process where cells become more mobile and adaptable, a trait often associated with cancer spreading and becoming harder to treat. These same tumors also showed changes in how they processed energy and handled stress, but they lacked the strong signs of an active immune attack that were seen in other tumors.
When the researchers looked at patient outcomes, the results were telling. For patients who received chemotherapy, having high levels of the helpful immune cells was linked to better survival and a lower chance of the cancer returning. In contrast, the presence of IL-17 cells did not show a clear benefit. While the statistical evidence was not strong enough to declare a definitive negative effect, the data suggested a trend where these tumors might be associated with a higher risk of the cancer coming back. The study indicates that tumors rich in IL-17 cells represent a unique type of disease: one that is less active in terms of immune defense and more focused on cellular changes that could make the cancer more resilient.
The researchers also examined the role of macrophages, a type of immune cell found in the tissue around the tumor. They found that when these cells were present in the tissue surrounding the cancer, they were linked to better outcomes for patients who received chemotherapy. However, if these same cells were found inside the clusters of cancer cells, they were associated with worse outcomes in patients who did not receive chemotherapy. This highlights how the location of immune cells matters just as much as their type. The study also looked at the balance between different immune cells, such as the ratio of helper cells to killer cells, but found that the overall amount of immune infiltration was a stronger predictor of survival than any single type of cell or ratio.
This work suggests that IL-17-producing cells mark a specific subtype of triple-negative breast cancer that behaves differently from the rest. These tumors appear to have turned down their immune defenses and turned up mechanisms that allow them to adapt and survive stress. Because these tumors look different at a molecular level, they might require different treatment strategies. The findings point toward the possibility that blocking the IL-17 pathway could be a useful approach, perhaps by combining it with other therapies to wake up the immune system or to stop the cancer from adapting. While the study does not prove that blocking IL-17 will cure the disease, it provides a clear biological reason to investigate this avenue further. By identifying this distinct group of patients, doctors may eventually be able to tailor treatments more precisely, moving away from a one-size-fits-all approach for triple-negative breast cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.